A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 5, 2012, Pages 807-814

  Levine, M N ^a   Gu, C ^a   Liebman, H A ^b   Escalante, C P ^c   Solymoss, S ^d   Deitchman, D ^e   Ramirez, L ^e   Julian, J ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d MONTREAL GENERAL HOSPITAL   (Canada)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

Apixaban; Cancer; Prevention; Thrombosis; Venous

Indexed keywords

APIXABAN; PLACEBO; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 10A; FIBRINOLYTIC AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; AGED; ARTICLE; BLADDER METASTASIS; BLEEDING; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LUNG METASTASIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MYELOMA; OUTCOME ASSESSMENT; OVARY METASTASIS; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VISCERAL METASTASIS; BLOOD; CANADA; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ANTAGONISM; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; ORAL DRUG ADMINISTRATION; PATHOLOGY; RISK ASSESSMENT; RISK FACTOR; TIME; UNITED STATES;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CANADA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FACTOR XA; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PILOT PROJECTS; PYRAZOLES; PYRIDONES; RISK ASSESSMENT; RISK FACTORS; THROMBOEMBOLISM; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84860495892     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04693.x     Document Type: Article

References (16)

1. Levine MN, Lee AY. Treatment of venous thromboembolism in cancer patients. Semin Thromb Hemost 1999; 25: 245-9.
2. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, Samosh M, Bramwell V, Pritchard KI, Stewart D, Goodwin P. Double blind randomised trial of very-low-dose warfarin for the prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-9.
3. Haas SK, Kakkar A, Kemkes-Matthes B, Freund M, Gatzemeier U, Heilmann L, von Tempelhoff GF, Brom J, Weidinger G. Prevention of venous thromboembolism with low-molecular-weight heparin in patients with metastatic breast or lung cancer: results of the TOPIC studies. J Thromb Haemost 2005; 3(Suppl. 1): OR059.
4. Perry JR, Julian JA, Laperriere NJ, Geerts W, Agnelli G, Rogers LR, Malkin MG, Sawaya R, Baker R, Falanga A, Parpia S, Finch T, Levine MN. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010; 8: 1959-65.
5. Agnelli G, Gussoni G, Bianchini C; PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009; 10: 943-9.
6. Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, Rossi D, Gentilini F, Crippa C, Galli M, Nozzoli C, Ria R, Marasca R, Montefusco V, Baldini L, Elice F, Callea V, Pulini S, Carella AM, Zambello R, Benevolo G, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol 2011; 29: 986-93.
7. Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AGG for the SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366: 601-9.
8. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-505.
9. Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5: 2368-75.
10. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361: 594-604.
11. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM, ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363: 2487-98.
12. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P, the ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double-blind trial. Lancet 2010; 375: 807-15.
13. Buller H, Deitchman D, Prins M, Segers S. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008; 6: 1313-18.
14. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-4.
15. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985; 69: 1375-81.
16. Eikelboom JW, Weitz J. New anticoagulants. Circulation 2010; 121: 1523-32.